Boehringer Ingelheim BI770371’s NCT06806852 trial – the “First patient i...

On June 17, 2025, the Department of New Experimental Therapeutics a...

View More

Selected to be AbbVie’s Phase 1 Partnerships for Excellence in Research (P1PER) Glob...

Department of New Experimental Therapeutics, Early-Phase 1 Drug Dev...

View More

Incyte INCA33890-First Administration of Investigational Cancer Drug in Asia (Global...

On February 18, 2025, the Department of New Experimental Therapeuti...

View More

Dr. Yuta Yamanaka presented the impact of renal dysfunction and pemetrexed administr...

Dr. Yuta Yamanaka presented the impact of renal dysfunction and pem...

View More

Dr. Tatsuki Ikoma Receives ESMO Targeted Anticancer Therapies (TAT) Asia Congress Tr...

Dr. Tatsuki Ikoma has been awarded the Travel Grant for the ESMO Ta...

View More

Selected for the Ministry of Education, Culture, Sports, Science and Technology (MEX...

In August 2024, Kansai Medical University was selected for the MEXT...

View More